Clinical Efficacy of Megadose Vitamin C in Sepsis

• Status: Not yet recruiting
• Trial end date: 2024-01-04
• Target enrollment: 0
• Participant gender: All

Summary

In this multicenter, randomized, single-blind, placebo-controlled clinical trial. Patients will be randomly assigned to receive Vitamin C or placebo for 4 days or until ICU discharge (whatever come first). The primary outcome is 28-day all-cause mortality.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Zhujiang Hospital
• Treatments: Ascorbic Acid

Criteria

Inclusion Criteria:

• Meets the diagnostic criteria for sepsis-3 developed by the American Society of Critical Care Medicine (SCCM)/European Critical Care Medicine Association (ESICM)

• Age ≥18 years old and age ≤80 years old.

• Procalcitonin ≥2 ng/ml

Exclusion Criteria:

• Age<18 years, or age>80 years.

• Pregnancy or lactating

• A solid-organ or bone marrow transplant patients.

• Patients with myocardial infarction within the past 3 months.

• Advanced pulmonary fibrosis .

• Patients with cardiopulmonary resuscitation before enrollment.

• HIV-positive patients.

• granulocyte-deficient patients.

• blood/lymphatic system tumors are not remission.

• patients with limited care (lack of commitment to full aggressive life support).

• patients with long-term use of immunosuppressive drugs or with immunodeficiency.

• patients with advanced tumors.

• patients combined with non-infectious factors leading to the death(uncontrollable major bleeding, brain hernia, etc.).

• surgically unresolved infection sources(such as some intraperitoneal infection etc.)

• patients allergic to vitamin c.

• patients with G6PD deficiency.